Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + trastuzumab + paclitaxel + cyclophosphamide + liposomal doxorubicin
- Development stage
- Unknown
- Lead developer
- Hospital Universitario HM Sanchinarro
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**AVANTHER** was a Phase 2, perioperative HER2-positive breast-cancer treatment regimen studied by Hospital Universitario Madrid Sanchinarro. It administered neoadjuvant bevacizumab, trastuzumab, and weekly paclitaxel before surgery, followed by adjuvant trastuzumab, cyclophosphamide, and non-pegylated liposomal doxorubicin supplied as Myocet. Bevacizumab neutralizes VEGF-A to suppress tumor angiogenesis; trastuzumab targets HER2; paclitaxel stabilizes microtubules; cyclophosphamide alkylates DNA after metabolic activation; and liposomal doxorubicin intercalates DNA and inhibits topoisomerase II. Myocet is a liposomal doxorubicin formulation, not interchangeable with conventional or pegylated liposomal doxorubicin. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01321775))
- Brand names
- AvastinHerceptinMyocet
- Other names
- AVANTHERbevacizumab + trastuzumab + paclitaxel + cyclophosphamide + Myocet
02
Targets
TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)TOP2A (DNA topoisomerase II)VEGFA (Vascular endothelial growth factor A)DNA
Beyond the preview
Go deeper on bevacizumab + trastuzumab + paclitaxel + cyclophosphamide + liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + trastuzumab + paclitaxel + cyclophosphamide + liposomal doxorubicin.